Current Illinois CancerCare Clinical Trials

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

Study Number: PROT001

Study Summary:
This is a non-significant risk, double-blinded, randomized, registrational study to compare the effectiveness of two digital, software only, medical devices (SaMD) (attune™ and cerena™) in reducing cancer-related anxiety and depression symptoms when used adjunctively with multidisciplinary (medical, psychosocial) oncology usual care regimens for up to 10 weeks.

Study population will consist of up to 553 participants with stage I-III breast cancer or stage I-III NSCLC. The primary endpoint is percent improvement in anxiety symptoms at Week 10 and secondary endpoints of percent improvement in depressive symptoms will be assessed at Week 12.

An interim analysis for efficacy and futility will be conducted once 236 participants have completed the study.

Status: Open

Open in Bloomington, Galesburg, Ottawa, Pekin and Peoria only

Study Coordinator(s)
  • Hannah S, 309-243-3603, hshearburn@illinoiscancercare.com
  • Courtney, 309-243-3660 cbrown@illinoiscancercare.com
  • Kelsey, 309-243-3618 kfay@illinoiscancercare.com

Study Link

« Search Again